Kalaris Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Kalaris Therapeutics

10/05/2025 24:05

Kalaris Therapeutics Inc KLRS.OQ KLRS.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Kalaris Therapeutics Inc is for a loss of 77 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "Strong Buy".​

Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $20.00​, above​ its last closing price of $3.48. ​​​

This summary was machine generated May 9 at 23:05 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)